polymorphism
The association between the lncRNA GAS5 rs145204276 indel
polymorphism and cancer risk is presented in Table 2. The pooled OR of
the ten relevant studies for different genetic models was elucidated.
There was no significant association between the lncRNA GAS5rs145204276 indel polymorphism with cancer risk under allelic model (delvs. ins) (OR: 0.98; 95%CI: 0.8024; 1.1941; p: 0.83;I2 : 94%); a recessive model (del/delvs. del/ins+ ins/ins) (OR: 1.09; 95%CI: 0.7822; 1.5251; p: 0.60;I2 : 88%); a dominant model (del/del+ del/insvs. ins/ins) (OR: 0.95; 95%CI: 0.7571; 1.2016; p: 0.69;I2 : 92%), an over-dominant model ( del/insvs. del/del+ ins/ins) (OR: 0.93; 95%CI: 0.8199; 1.0549; p: 0.26;I2 : 71%); a homozygote contrast model (del/delvs. ins/ins) (OR: 1.06; 95%CI: 0.6964; 1.6162; p: 0.78;I2 : 92%); an additive model (del/delvs. ins/del) (OR: 1.15; 95%CI: 0.9055; 1.4682; p: 0.25;I2 : 74%) and a heterozygote contrast model
(del/ins vs. ins/ins) (OR: 0.94; 95%CI: 0.7744; 1.1403; p: 0.53;I2 : 87%) (Figure 2).
Furthermore, in the subgroup analysis based on cancer types, the
rs145204276 indel polymorphism was associated with a lower risk of
gastric cancers in the population in different genetic models; allelic
model (del vs. ins) (OR: 0.78; 95%CI: 0.6916; 0.8701; p: 0.00;I2 : 40%); a recessive model (del/delvs. del/ins+ ins/ins) (OR: 0.73; 95%CI: 0.5565; 0.9603; p: 0.02;I2 : 00%); a dominant model (del/del+ del/insvs. ins/ins) (OR: 0.73; 95%CI: 0.6278; 0.8404; p: 0.00;I2 : 29%); an over-dominant model ( del/insvs . del/del+ ins/ins) (OR: 0.79; 95%CI: 0.6809; 0.9161; p: 0.00;I2 : 45%); a homozygote contrast model (del/delvs. ins/ins) (OR: 0.64; 95%CI: 0.4861; 0.8529; p: 0.00;I2 : 38%) and a heterozygote contrast model
(del/ins vs. ins/ins) (OR: 0.75; 95%CI: 0.6394; 0.8683; p: 0.00;I2 : 40%). Furthermore, in the subgroup
analysis based on the source of control, we did not find any significant
association between the polymorphism and the subgroup investigations
(Table 2).